Navigation Links
Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain
Date:12/9/2009

SAN DIEGO, Dec. 9 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced top-line efficacy and safety results from the Tulip PETAL Study (703 Study), its fifth Phase 2 clinical trial using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis.

"The efficacy and safety data from the Tulip PETAL Study are consistent with what we have seen in our previous elagolix studies. Women recognize significant improvement in endometriosis symptoms across multiple time points using elagolix, coupled with an excellent safety profile," said Chris O'Brien, M.D., Chief Medical Officer at Neurocrine. "Although certain daily efficacy scales employed in this trial will not be used in subsequent trials, we have and will continue to obtain important information from this Phase 2 study. Given the placebo response in some of the secondary efficacy endpoints, we plan to perform extensive analyses to understand the differences between North American and Central Eastern European clinical trial sites and subjects, the impact of trial design differences and patient baseline characteristics, and continue our assessment of appropriate statistical methods as we plan for our pivotal trials."

Tulip PETAL Study Design and Baseline Characteristics

The Tulip PETAL study was conducted in six countries in the Eastern European region (Romania, Poland, Ukraine, Hungary, Russia and Bulgaria). The study randomized 174 patients with a laparoscopic diagnosis of endometriosis into four treatment arms: elagolix 150 mg once daily, elagolix 250 mg once daily, leuprorelin monthly depot (Prostap SR®), or placebo; in a double-blind, double-dummy design. After completion of the initial three months of treatment, place
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Neurocrine Biosciences Amends Corporate Headquarters Lease
2. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
3. Neurocrine Biosciences Secures Committed Equity Financing Facility
4. Neurocrine Biosciences Reports Second Quarter 2009 Results
5. Webcast Alert: Neurocrine Biosciences Announces 2nd Quarter 2009 Earnings Results
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2009 Financial Results
7. Neurocrine Biosciences to Present at the 8th Annual Needham Life Sciences Conference
8. Neurocrine Biosciences to Present at the Deutsche Bank 34th Annual Health Care Conference
9. Neurocrine Biosciences Reports First Quarter 2009 Results
10. Neurocrine Announces Work Force Restructuring
11. Neurocrine Biosciences to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... October 20, 2014 , A ... disorders and the delivery of care has revealed changing ... worrying inequalities in the provision of healthcare services across ... commissioned by United European Gastroenterology (UEG), have been announced ... public awareness of the burden of GI disorders across ...
(Date:10/20/2014)... 20, 2014 OncLive® ... Cancer Center at Thomas Jefferson University has joined ... the Strategic Alliance Partnership program, the Sidney Kimmel ... to raise awareness of the Center’s cutting-edge research ... projects. Clinicians and other health care professionals from ...
(Date:10/19/2014)... The Latin American hardware encryption display ... America with analysis and forecast of revenue. This market ... expected to reach $2,366.8 million by 2018, at a ... through the TOC of the Latin American hardware encryption ... analysis provided. It also provides a glimpse of the ...
(Date:10/19/2014)... 19, 2014 The Asia-Pacific Bromine ... in Asia-Pacific with analysis and forecast of revenue. ... Pacific Bromine Market report, to get an idea ... a glimpse of the segmentation in the Asia-Pacific ... and figures. , http://www.micromarketmonitor.com/market/asia-pacific-bromine-6741503144.html , ...
Breaking Biology Technology:Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 3
... Sept. 16 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc.,(TSX:SBS), a ... metabolic and cardiovascular diseases, today announced that it,is ... human clinical trial of,plant-produced insulin now that the ... application has passed. SemBioSys submitted,the application in July ...
... of a Phase ... of Seasonal Influenza Vaccine, ROCKVILLE, Md., Sept. 16 ... volunteers in a Phase,II clinical trial of its virus-like particle ... clinical trial will,evaluate the safety and immunogenicity of different doses ...
... Inc. (the,"Company" or "MIGENIX") (TSX: MGI; OTC: ... diseases, reports financial results for the three,months ... corporate update on its programs,and other matters., ... Omiganan 1% gel (Omigard(TM)/CPI-226/MX-226; topical cationic peptide;,prevention ...
Cached Biology Technology:SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND 2SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND 3Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate 2Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate 3Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate 4Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate 5MIGENIX Reports First Quarter Fiscal 2009 Financial Results 2MIGENIX Reports First Quarter Fiscal 2009 Financial Results 3MIGENIX Reports First Quarter Fiscal 2009 Financial Results 4MIGENIX Reports First Quarter Fiscal 2009 Financial Results 5MIGENIX Reports First Quarter Fiscal 2009 Financial Results 6MIGENIX Reports First Quarter Fiscal 2009 Financial Results 7MIGENIX Reports First Quarter Fiscal 2009 Financial Results 8MIGENIX Reports First Quarter Fiscal 2009 Financial Results 9MIGENIX Reports First Quarter Fiscal 2009 Financial Results 10MIGENIX Reports First Quarter Fiscal 2009 Financial Results 11
(Date:10/14/2014)... 2014)—It,s been millions of years since T. rex ... by Ohio University scientists is breathing life back into ... dinosaur snouts. The research has important implications for how ... to enhance the sense of smell and cool their ... Ohio University doctoral student Jason Bourke, lead author of ...
(Date:10/14/2014)... is how to produce enough food to feed the ... Agriculture Organization of the United Nations predicts that food ... to feed a growing global population, and plants are ... production. Plants—grains, cereals, fruits, vegetables, and more—feed humans ... must tap into our knowledge of how plants work ...
(Date:10/14/2014)... fish oil supplements, rich in omega-3 fatty acids, do not ... which the heart can beat as fast as 150 beats ... the Montreal Heart Institute were published in the Journal ... , For the trial, 337 patients with atrial fibrillation not ... of fish oil a day or to placebo for up ...
Breaking Biology News(10 mins):Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3
... , , SEATTLE, Dec. 18 Pacific ... a leading provider of specialized central laboratory and contract research ... that were voted upon at the Company,s Annual Meeting on ... approve a change in the Company,s name to "Pacific Biomarkers, ...
... PITTSBURGHResearchers at Carnegie Mellon University,s National Robotics Engineering ... computer vision and machine learning to inspect and grade ... quality tasks that until now could only be ... fall, the machine classified and sorted harvested plants more ...
... 17, 2009 Time and time again, it has been ... risks associated with the comorbidities of obesity. With only ... Institutes of Health exercise guidelines of 300 minutes/week, a study ... Nutrition Education and Behavior explores the paradox that exists ...
Cached Biology News:Pacific Biometrics, Inc. Stockholders Approve Company Name Change to Pacific Biomarkers, Inc. 2Pacific Biometrics, Inc. Stockholders Approve Company Name Change to Pacific Biomarkers, Inc. 3Pacific Biometrics, Inc. Stockholders Approve Company Name Change to Pacific Biomarkers, Inc. 4Carnegie Mellon engineers develop machine that visually inspects and sorts strawberry plants 2Negative emotions outweigh intent to exercise at health clubs 2
Syd-2 (cL-19)...
... isolation and affinity purification of small ... Hydrophobic, monodisperse magnetic particles (2.8 m ... further surface activation is not required. ... optimal orientation for affinity purification of ...
ZO-2 (H-110)...
p-Bcl-2 (Thr 74)...
Biology Products: